Psoriasis

Bruce Sherman, MD, FCCP, FACOEM, underlines the impact of health inequities for patients diagnosed with psoriasis.

Maria Lopes, MD, MS, provides an overview of the PASI scoring system.

Amy McMichael, MD, discusses the impact of psoriasis on a patient’s quality of life.

Ryan Haumschild, PharmD, MS, MBA, leads a panel discussion highlighting the current prevalence of psoriasis.

Diagnoses of psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, or undifferentiated inflammatory arthritis saw a dramatic decline during the early stages of the COVID-19 pandemic.

An immune-mediated relationship between the brain and skin has been hypothesized in previous studies about psoriasis.

A review of available literature, although limited, has pointed to a link between pediatric psoriasis and anxiety and depression. Previous research has made a clear association between psoriasis and mood disorders in adults.

Data on the use of biologics for psoriasis among patients with a history of cancer have remained sparse. However, new findings provide the largest amount of real-world data on the use of the biologic secukinumab in these patients.

A prospective study found that patients and providers saw benefits while using a virtual assistant integrated into a teledermatology program.

A brief report found that a need for prior authorization affected biologic approval wait times for patients with psoriasis, especially those with private insurance.

Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.

Black and Hispanic patients living with chronic inflammatory skin disease (CISD) have more barriers to care compared with White patients with CISD, according to a recent study.

Quality of life and sleep quality were both negatively impacted by pruritus when it occurs with psoriasis, according to a recent study.

Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.

In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.

The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks on the positive safety and efficacy profile shown in the DERMIS-1 and DERMIS-2 trials exploring use of roflumilast cream in patients with chronic plaque psoriasis, including those with intertriginous disease.

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

A decade’s worth of retrospective data from over 1 million patients with end-stage renal disease (ESRD) undergoing dialysis showed that psoriasis may be protective against pneumonia in these patients.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA for the treatment of plaque psoriasis in patients aged 12 and older.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.